SLC5A2 and hydrops fetalis: Taken together, the totality of evidence supports the feasibility, safety, and likely mortality benefit of initiating SGLT2 inhibitors prior to discharge in stabilized acute HF patients—aligning with high-intensity, protocol-driven strategies that prioritize getting foundational therapy on board before patients leave the hospital.